Tonix Pharmaceuticals Holding Corp. (TNXP) Form 8-K — Nov 9, 2026
Tonix Pharmaceuticals reported Q3 2026 net product revenue of approximately $17.2 million, up from $3.3 million a year earlier, led by TONMYA net sales of roughly $15 million, up 37% quarter-over-quarter. Total prescriptions rose 28% QoQ to 16,375 with covered lives at ~166 million, supported by a sales force expansion to ~150 reps. The company posted a net loss of $53.3 million ($2.89 per share) as R&D and SG&A spending roughly doubled year-over-year following TONMYA's launch. Cash fell to approximately $163 million from $207.6 million at year-end, with operating cash burn of $125.6 million for the nine months.
Key figures
- Revenue
- 17234000
- Total Assets
- 242426000
- Cash Position
- 162793000
- Shares Outstanding
- 19431516
- Cash runway
- into early third quarter of 2027
- Sales force
- approximately 150 reps
- Covered lives
- approximately 166 million (~53% of US)
- Revenue 9m 2026
- 37656000
- Refill growth qoq
- 56%
- Total liabilities
- 42941000
- Stockholders equity
- 199485000
- Tonmya q3 net sales
- $15.0 million, up 37% quarter-over-quarter
- Total current assets
- 192135000
- Operating loss q3 2026
- 55432000
- Prescription growth qoq
- 28%
- Post quarter equity raise
- $1.5 million
- Tonmya total prescriptions
- 16375
- New prescription growth qoq
- 17%
- Zembrace tosymra revenue q3
- $2.2 million vs $3.3 million prior year
- Net cash used operating 9m 2026
- $125.6 million vs $60.2 million prior year
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.